Skip to main content


Anti-obesity medications

12-14-2018 | Sleep apnea | Editorial | Article

Diabetes and obstructive sleep apnea syndrome: Double trouble

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition.

John Wilding

10-05-2018 | Lorcaserin | EASD 2018 | News

Weight loss with lorcaserin linked to improved glycemic profile

Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.


Lancet 2018; doi:10.1016/S0140-6736(18)32328-6
EASD Annual Meeting; Berlin, Germany: 1–5 October 2018

08-26-2018 | Lorcaserin | Highlight | News

Neutral cardiovascular safety for lorcaserin in CAMELLIA-TIMI 61

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.


N Engl J Med 2018; doi:10.1056/NEJMoa1808721
N Engl J Med 2018; doi:10.1056/NEJMe1810855

08-17-2018 | Semaglutide | Highlight | News

Semaglutide shows promise for weight management

Findings from a dose-ranging phase II trial published in The Lancet suggest that semaglutide, in combination with lifestyle intervention, may aid weight loss in people with obesity who do not have diabetes.


Lancet 2018; doi:10.1016/S0140-6736(18)31773-2
Lancet 2018; doi:10.1016/S0140-6736(18)31826-9

04-13-2018 | Obesity | Review | Article

Treatment of adolescent obesity

Steinbeck KS et al. Nature Reviews Endocrinology 2018. doi: 10.1038/s41574-018-0002-8

04-03-2018 | Obesity | Review | Article

Racial disparities in obesity treatment

Byrd AS, Toth AT, Stanford FC. Curr Obes Rep 2018; Advance online publication. doi: 10.1007/s13679-018-0301-3

03-05-2018 | Obesity | Review | Article

Future pharmacotherapy for obesity: New anti-obesity drugs on the horizon

Srivastava G, Apovian C. Curr Obes Rep 2018; Advance online publication. doi: 10.1007/s13679-018-0300-4

01-05-2018 | Cardiovascular outcomes | Review | Article

Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: Established and emerging agents

Saxon DR, Rasouli N, Eckel RH. Drugs 2018; 78: 203–214. doi: 10.1007/s40265-017-0857-3

10-13-2017 | Obesity | Review | Article

Current pharmacotherapy for obesity

​​​​​​​Nat Rev Endocrinol 2017; 14: 12–24. doi: 10.1038/nrendo.2017.122

Gitanjali Srivastava, Caroline M. Apovian

11-06-2017 | Prediabetes | News

Lifestyle interventions have most staying power for diabetes prevention

A meta-analysis shows that although medications and lifestyle changes can both reduce the risk for type 2 diabetes in high-risk patients, only lifestyle modifications have a sustained effect.


JAMA Intern Med 2017; Advance online publication

08-23-2017 | Obesity | Review | Article

Weight management in patients with type 1 diabetes and obesity

Mottalib A et al. Curr Diab Rep 2017; 17: 92. doi: 10.1007/s11892-017-0918-8

07-31-2017 | Diabetes prevention | Review | Article

Pharmaceutical interventions for diabetes prevention in patients at risk

Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017; 1: 13–24. doi: 10.1007/s40256-017-0239-y

06-23-2017 | Obesity | Review | Article

Pharmacotherapy in the management of pediatric obesity

Kelly AS, Fox CK. Curr Diab Rep 2017; 17: 55. doi: 10.1007/s11892-017-0886-z

01-18-2017 | Obesity | Review | Article

Medical management of diabesity: Do we have realistic targets?

Pappachan JM, Viswanath AK. Curr Diab Rep 2017; 17: 4. doi: 10.1007/s11892-017-0828-9

07-07-2017 | Liraglutide (obesity) | Updates | News

NICE evidence summary for liraglutide use in obese and overweight adults

The National Institute For Health and Care Excellence has issued an evidence summary to support use of the glucagon-like peptide-1 receptor agonist liraglutide in obese and overweight individuals with risk factors, such as dysglycemia.

05-14-2017 | Obesity | Review | Article

Medication use for the treatment of diabetes in obese individuals

Wilding JPH. Diabetologia 2017; 61: 265–272. doi: 10.1007/s00125-017-4288-1

04-19-2017 | Obesity | Review | Article

Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?

Roberts CA et al. Acta Diabetol 2017; 54: 715–725. doi: 10.1007/s00592-017-0994-x

01-20-2017 | Obesity | Patient and physician’s perspective | Article

Behavior modification: A patient and physician’s perspective

A patient affected by obesity discusses her experience of living with the disease and using many different weight loss approaches until finding a lifestyle program that was appropriate for her metabolism.

05-10-2017 | Liraglutide (T2DM) | News

Liraglutide link with pancreatitis unlikely

Taking the glucagon-like peptide-1 receptor agonist liraglutide does not increase patients’ risk for acute pancreatitis during more than 3 years of treatment, show two reports analyzing the LEADER and SCALE trials.


Diabetes Care 2017; Advance online publication

05-04-2017 | Obesity | News

Assessing diabetes risk could optimize effectiveness of weight loss therapy

Targeting obese patients for weight-loss therapy according to their cardiometabolic status could much improve its effectiveness for diabetes prevention, say researchers.


Diabetes Care 2017; Advance online publication

image credits